Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced data from the APHINITY trial in a poster spotlight discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The poster, titled Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial, outlines data from an exploratory analysis of the Phase 3 study that randomized 4,805 patients with histologically centrally confirmed HER2+ early breast cancer into two arms, one which received standard adjuvant chemotherapy and trastuzumab plus pertuzumab, and one which received standard adjuvant chemotherapy Read More
Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from FLEX, the large-scale, prospective, observational breast cancer study, has been selected for presentation in six posters during the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The posters, being presented at different sessions throughout SABCS 2020, focus on underrepresented or underserved populations or types of breast cancer. “FLEX could be one of the most valuable, impactful, flexible, and inclusive studies in breast cancer research to date,” said Laura Lee, M.D., Surgical Oncology Specialist Read More
Findings confirm subanalysis of STO-3 trial and provide foundation for consideration of de-escalation of treatment in post-menopausal patients guided by genomic testing IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, presented data from the FOCUS trial that show the clinical utility of MammaPrint® in older breast cancer patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The poster, The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients, outlines data from the FOCUS trial, a population-based cohort of over 2,000 people that included all consecutive breast cancer patients over 65 years old diagnosed between 1997 and 2004 in the Comprehensive Read More
Co-development program will utilize next-generation digital pathology platform and AI-based technology to provide real-time genomic testing results Partnership to create new products enabling faster access to predictive information in treatment planning for patients with breast cancer IRVINE, CALIF., AMSTERDAM and NEW YORK – November 18, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, and Paige, a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to Read More
Variety of data confirm the importance of applying genomic analysis to explore and improve outcomes for subpopulations of breast cancer patients IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – NOVEMBER 17, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that it will present new data from ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS 2020), taking place virtually December 8-11, 2020. These data, which build upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to consistently inform optimal treatment planning, highlight Agendia’s many trials in progress that will ultimately impact patient treatment and outcomes. Specific data selected for Read More
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference, which takes place November 30 – December 3, 2020. Agendia Chief Executive Mark Straley will be accompanied by Agendia Chief Financial Officer Brian Dow for one-on-one Investor meetings on Monday, November 30; meetings may be requested exclusively through Piper Sandler. Additionally, a recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3, and on the Agendia website at https://agendia.com/news/. Click here to view the pre-recorded presentation About Agendia Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and Read More
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.